Consensus EPS · Q1 2026
$0.79
Consensus revenue · Q1 2026
$5.2B
Analysts
15
Expected report
Jul 22, 2026
What to watch
- Analyst ratings: Downgrades trending
Think you can beat Wall Street?
Predict Boston Scientific (BSX) Q1 2026 revenue & EPS, earn XP, and climb the leaderboard.
Analyst consensus
Based on estimates from 15 analysts.
| Metric | Low | Consensus | High |
|---|---|---|---|
| Revenue | $5.1B | $5.2B | $5.3B |
| EPS | $0.77 | $0.79 | $0.83 |
| EBITDA | $1.2B | $1.2B | $1.2B |
| EBIT | $800.8M | $806.8M | $821.7M |
| Net income | $1.2B | $1.2B | $1.3B |
Historical beat/miss
Actual reported results vs. analyst consensus at the time. Positive = beat, negative = miss.
| Period | Rev. actual | Rev. est. | Rev. surprise | EPS actual | EPS est. | EPS surprise |
|---|---|---|---|---|---|---|
| Q4 2025 | $5.3B | $5.3B | +0.2% | $0.80 | $0.78 | +2.5% |
Estimate revisions
How analyst consensus estimates have changed over the past 90 days.
Revision trends appear once we have collected at least two daily snapshots for this period.
Community vs analysts
See how the TickerLeague crowd's forecast stacks up against Wall Street.
Be the first to predict
No community consensus for Boston Scientific (BSX) Q1 2026 yet. Make a prediction to start the crowd forecast.
Analyst price target
Based on price targets from 10 analysts.
| Low | Consensus | Median | High | Current | Upside |
|---|---|---|---|---|---|
| $55.00 | $83.84 | $77.00 | $120.00 | $48.55 | +72.7% |
Upside calculated vs most recent trading price of $48.55.
Analyst ratings
Consensus: Buy — based on 44 analyst ratings.
12-month trend
Recent analyst actions
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Jun 4, 2026 | Truist Securities | maintain | Buy | Buy |
| Jun 3, 2026 | BTIG | maintain | Buy | Buy |
| Jun 1, 2026 | Canaccord Genuity | maintain | Buy | Buy |
| May 29, 2026 | Wolfe Research | downgrade | Outperform | Peer Perform |
| May 28, 2026 | Wells Fargo | downgrade | Overweight | Equal Weight |
| May 28, 2026 | Leerink Partners | maintain | Outperform | Outperform |
| May 28, 2026 | Citigroup | maintain | Buy | Buy |
| May 28, 2026 | Barclays | maintain | Overweight | Overweight |
| May 19, 2026 | Baird | maintain | Outperform | Outperform |
| May 18, 2026 | Needham | maintain | Buy | Buy |
Boston Scientific (BSX) Key Financials
Charts, filings, and peer comparison for every metric
Frequently asked questions
Explore more
Deep-dives across the income statement, cash flow, capital return, and valuation